Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Melanoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hemangiosarcoma 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
peginterferon alfa-2a × 1 year × Clear all
NCT07288112 2026-04-14

DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma

Diakonos Oncology Corporation

Phase 1/2 Recruiting
35 enrolled
Dermatologic

Melanoma

NCT05799612 2026-02-13

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Sarcoma

Hemangiosarcoma

NCT02201459 2025-10-02

PETALs

Hospices Civils de Lyon

Phase 3 Completed
200 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡